Navigation Links
Avexa Reports Positive Phase IIb Result

und 1.4 million people in North America and around 2.2 million people in Europe have HIV.

Once on therapy, patients with HIV will typically take a minimum of 3 drugs daily in combination. This may increase as a patient progresses into 2nd and 3rd line therapy or into salvage therapy, when patients develop what is commonly referred to as AIDS. Second line patients are defined as patients who show resistance to at least one class of HIV drugs, while 3rd line and salvage patients typically have resistance to multiple drugs and drug classes. Avexa aims to position ATC as the NRTI of choice for treatment of patients in 2nd and 3rd line therapy and salvage therapy, as well as the growing number of treatment naive patients presenting with HIV virus resistant to current front line therapies. In 2005 HIV drugs generated sales globally of USD $6.6 billion, with NRTIs representing greater than 50% of the overall market.

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials.

Technical Data

Trial Design

AVX-201 is a randomised, double blind study of two doses of ATC compared to lamivudine (3TC) in treatment-experienced HIV-1 infected patients with the M184V mutation. Patients were randomised to receive 600mg or 800mg ATC twice daily, or 3TC twice daily, for 21 days, in a blinded fashion. The primary endpoint of the study is the change in the amount of virus in the blood (viral load) after 21 days treatment.

After day 2
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avexas Apricitabine Clinical Trial Update
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Reports Positive Phase IIb Result
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "An Introduction to Medical ... November 2-3, 2015)" conference to their offering. ... comprehensive introduction to the regulations and requirements that ... be highly interactive, using real life examples and ...
(Date:9/2/2015)... 2, 2015  Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ... "An Introduction to the Medical Devices Directive (London, ... their offering. This seminar provides ... legislation. It will explain the Directives and which ... how to choose one and outline what a ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( ... "New EU Pharmacovigilance Legislation (London, UK - November 16-17, ... The 15 new EU modules concerning Pharmacovigilance are a ... conducted in Europe . The intention ... and their requirements, examine how they overlap and fit ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... 2011 Amarin Corporation plc (Nasdaq: AMRN ... cardiovascular disease, today announced that Executive Chairman and Chief ... EDT on April, 6, 2011 at the 10th Annual ... President, John Thero, will be available at the conference ...
... VIVUS, Inc. (Nasdaq: VVUS ) today announced that ... in a poster presentation at the 60th Annual Scientific Meeting ... 2011 in New Orleans, Louisiana. Following are details ... presented in Hall F of The Ernest N. Morial Convention ...
Cached Medicine Technology:Amarin to Present at the 10th Annual Needham Healthcare Conference 2Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting 2
(Date:9/3/2015)... ... ... scar is an unavoidable result of incision or injury to the skin. Unsightly as it ... The appearance of a scar is dependent on many factors – the size and depth ... fade to near invisibility on their own over a period of months,” says Dr. ...
(Date:9/3/2015)... ... September 03, 2015 , ... The ... Clinicians Report of Provo, Utah. The Clinicians Report is a leading information source ... dentists located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated ...
(Date:9/3/2015)... ... , ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA ... will introduce a segment that discusses why it is important for the workplace to ... fostered in any working environment. , Employers are out billions of dollars year after ...
(Date:9/2/2015)... ... ... The Aspen Clinic (TAC), located in Basalt, Colorado, today announced an ... in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director of TAC, ... - we are much more than a gym. Our fitness and wellness retreats ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand ... the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or two short ... given guide RNA (sgRNA or crRNA) to create a break in the target DNA ...
Breaking Medicine News(10 mins):Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... 23 NxStage Medical, Inc.,(Nasdaq: NXTM ), a ... million private placement of its common stock and,warrants. The ... stock at a price of $4.50 per share and ... an exercise price of $5.50 per share,which price may ...
... 23 Dr. Nancy Minshew, a,leading researcher on the ... work in a presentation co-sponsored by the Pennsylvania,Cyber Charter ... diagnosed with autism. Students with,autism and other special needs ... its mission, is committed to focusing on the needs ...
... University,Medical Center (MUMC) now offers a type of ... the belly button. It,s called single,incision laparoscopic surgery, ... in the SILS technique. One of them is ... remove the gallbladder through a,1cm. incision in the ...
... MDNG, a publication that,reaches nearly a quarter ... discussion that will provide physicians an opportunity,to speak ... unique,practice model has made him a household name. ... 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ., ...
... 500,000 to make a world of difference for Singer Songwriter Katie ... Reider Beginning ... years, Cincinnati-based,singer songwriter Katie Reider, age 29, has inspired the hearts ... within. Fans across the country are banding together to help Katie,during ...
... ... health in the Western world, the, Omega-3 story may someday be viewed ... - William S. Harris, PhD, American ... Nutrition (2003), COLUMBUS, Ohio, May 23 If anyone needed another reason,to ...
Cached Medicine News:Health News:NxStage Announces $43 Million Private Placement of Equity Securities 2Health News:NxStage Announces $43 Million Private Placement of Equity Securities 3Health News:NxStage Announces $43 Million Private Placement of Equity Securities 4Health News:Dr. Nancy Minshew, Autism Researcher, to Speak at Regional Learning Alliance in Cranberry Township 2Health News:SILS Surgical Technique Now Available at MUMC 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 3Health News:Announcing Another Great Reason to Eat Chocolate 2
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Bone Curette, 170 mm...
Bone Curette, 145 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Medicine Products: